JC Polyomavirus in Prostate Cancer—Friend or Foe?
Cancers · 21.05.2025 · 17 (10) · 1725
DOI: 10.3390/cancers17101725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.05.2025. Verfasst von Jacek Kiś und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Oncological Urology, 1st Clinical Military Hospital with Outpatient Clinic in Lublin, 20-049 Lublin, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, Poland, Medical University of Lublin.
Abstract (Originalsprache)
Background/Objectives: Recently, many researchers have evaluated various viruses, including polyomaviruses (JCV, BKV) and EBV, as potential factors playing a role in the development and/or progression of prostate cancer (PCa), one of the most common cancers in men. Therefore, we aimed to assess the frequency of the JCPyV DNA in tissue collected from PCa patients.
Methods
We detected the presence of viral DNA (PCR) in 49.6% of clinical samples, including 71.9% with single EBV infection and 28.1% with EBV/JCV co-infection. We did not detect BKV or a single JCV infection. Therefore, we compared patients with EBV mono-infection with EBV/JCV co-infected patients in the context of risk group, Gleason score, and TNM classification.
Results
Our results showed differences in clinicopathological features between single EBV infection and EBV/JCV co-infection. In the group of patients with single EBV infection, most patients were classified as medium/high risk, while in the group with EBV/JCV co-infection, most patients were classified as low risk.
Conclusions
Among patients with single EBV infection, a more advanced stage of cancer was observed than in EBV/JCV co-infection. Moreover, the level of anti-EBVCA and anti-EBNA antibodies as well as EBV load was higher in the case of single infection compared to EBV/JCV co-infection. Higher antibody levels were detected in more advanced tumor stages in single EBV infection. Does JCV only “reside” in prostate cells or is it a co-factor in EBV infection? In light of these studies, there is a need to clarify the role of JCV virus in the development and/or progression of prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General and Oncological Urology, 1st Clinical Military Hospital with Outpatient Clinic in Lublin, 20-049 Lublin, Poland.
- Department of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, 20-093 Lublin, Poland.
- Faculty of Human Sciences, University of Economics and Innovation, 20-209 Lublin, Poland.
ORCID-Profile: Dominika Sikora, Małgorzata Polz-Dacewicz
Förderung
- Medical University of Lublin, Poland
- Medical University of Lublin
Zitieren
APA
Kiś, J., Sikora, D., Jarosz, M. J., & Polz-Dacewicz, M. (2025). JC Polyomavirus in Prostate Cancer—Friend or Foe?. Cancers, 17(10), 1725. https://doi.org/10.3390/cancers17101725
Vancouver
Kiś J, Sikora D, Jarosz MJ, Polz-Dacewicz M. JC Polyomavirus in Prostate Cancer—Friend or Foe?. Cancers. 2025;17(10):1725. doi:10.3390/cancers17101725
BibTeX
@article{Ki2025,
author = {Kiś, Jacek and Sikora, Dominika and Jarosz, Mirosław J and Polz-Dacewicz, Małgorzata},
title = {JC Polyomavirus in Prostate Cancer—Friend or Foe?},
journal = {Cancers},
year = {2025},
volume = {17},
number = {10},
pages = {1725},
doi = {10.3390/cancers17101725}
}
EUVIMED